Linh McClure
Adult Health · Maitland, FLNPI 1033623269
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 517 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,424 and has fallen 96.1% since, to $132 in 2025. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Johnson & Johnson$1K
- AbbVie$1K
- UCB, Inc.$843
- Pfizer$681
- GSK$556
- plus $3K from 18 others
What the payments were for
- Food & beverage$10,07799%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 125 | $2,376 |
| Johnson & Johnson | 59 | $1,492 |
| AbbVie | 53 | $1,097 |
| UCB, Inc. | 46 | $843 |
| Pfizer | 74 | $681 |
| GSK | 23 | $556 |
| Lilly USA, LLC | 26 | $544 |
| AstraZeneca(2 entities) | 20 | $378 |
| Aurinia Pharma U.S., Inc. | 22 | $356 |
| Mallinckrodt Hospital Products Inc. | 11 | $265 |
| ANI Pharmaceuticals, Inc. | 12 | $246 |
| Sobi, Inc | 8 | $159 |
| Genentech USA, Inc. | 4 | $156 |
| Ferring Pharmaceuticals Inc. | 5 | $125 |
| E.r. Squibb & Sons, L.L.C. | 6 | $123 |
| Sanofi | 6 | $122 |
| Idorsia Pharmaceuticals US Inc | 1 | $119 |
| Paratek Pharmaceuticals, Inc. | 1 | $116 |
| Neurocrine Biosciences, Inc. | 1 | $109 |
| Radius Health, Inc. | 5 | $94 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $68 |
| Boehringer Ingelheim | 3 | $53 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,137 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 128 | $962,112 |
| Enbrel SureclickEtanercept | 129 | $944,489 |
| Xeljanz XrTofacitinib Citrate | 59 | $347,353 |
| RinvoqUpadacitinib | 47 | $308,181 |
| KevzaraSarilumab | 64 | $270,375 |
| BenlystaBelimumab | 44 | $215,978 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $122,145 |
| Actemra ActpenTocilizumab | 23 | $99,019 |
| Enbrel MiniEtanercept | 13 | $95,026 |
| SimponiGolimumab | 16 | $93,932 |
| Orencia ClickjectAbatacept | 17 | $93,186 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $60,664 |
| Hydroxychloroquine Sulfate | 381 | $10,283 |
| Mycophenolate Mofetil | 61 | $6,358 |
| Leflunomide | 101 | $4,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,097 | $308,18147 claims |
| SanofiKevzara | $122 | $270,37564 claims |
| GSKBenlysta | $556 | $215,97844 claims |
| Johnson & JohnsonSimponi | $1,492 | $93,93216 claims |
| UCB, Inc.Cimzia (2 Pack) | $843 | $60,66411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Maitland
- Patricia PagnottaMaitland$409K
- Cynthia OteroMaitland$31K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Jennifer GodshallTampa$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.